source
- Regeneron's LAG-3 inhibitor fianlimab fails Phase 3 skin cancer trialRegeneron announced that its experimental LAG-3 inhibitor fianlimab did not meet its primary endpoint in a late-stage trial for a skin cancer indication. The Phase 3 study was designed to evaluate…
- Experts debate testing Merck’s Ervebo vaccine for DRC Ebola outbreak amid lack of approved shotThe Democratic Republic of the Congo confirmed a new Ebola outbreak at the end of May, making it the fourth largest on record. The virus is spreading in a conflict-affected region, complicating con…